International Flavors & Fragrances (IFF) presented its latest turnaround update at Barclays’ 19th Annual Global Consumer Conference on Sept. 10, 2026. Chief Executive Erik Fyrwald said the company is moving from a broad "one‑stop shop" to three focused end‑to‑end businesses – Scent, Taste and Health & Biosciences – after separating the Food Ingredients unit.
Shares traded at $84.07, down 0.28% from the prior close of $84.31, near the top of a 52‑week range of $59.14 to $89.32. The stock has risen 26.5% year‑to‑date and nearly 34% over the past year, giving IFF a market capitalisation of $21.45 billion.
Leverage has improved markedly, falling from 4.5 times debt‑to‑EBITDA to 2.5 times since Fyrwald took the helm in early 2024. The company expects leverage to stay between 2.0 times and 2.5 times after the Food Ingredients divestiture, which is slated to close in the first half of 2025 and is projected to generate about $3.8 billion in proceeds. IFF also announced a $2.5 billion share‑buyback programme.
The current ratio stands at 2.06 and InvestingPro assigned IFF a "GOOD" financial‑health score of 2.56. Pro forma growth over the past two years is 4 %, described as the low end of the mid‑single‑digit target range. The commercial win rate target has been lifted from 30 % to 35 %.
Customer mix is roughly evenly split among very large, medium‑size and smaller accounts. The firm is targeting low‑single‑digit growth in the second half of 2024 and expects new fermenter capacity for Health & Biosciences to come online in early 2025, with additional capacity additions through 2028. New fragrance molecule launches are planned from late 2024 into 2027, with material revenue impact anticipated from late 2027 onward.
Four pillars underpin the turnaround: engaged people, customer obsession, an innovation powerhouse and operating‑excellence. In Scent, IFF highlighted ENVIROCAP encapsulation, SENSORA Pro‑Fragrances and a captive molecule pipeline spanning biotech, synthetic chemistry and natural categories. In Taste, modulation platforms aim to reduce sugar, salt and fat while supporting high‑protein beverages linked to GLP‑1 drug trends.
Fyrwald noted that active cosmetics could represent a white‑space opportunity for bolt‑on acquisitions following the earlier sale of Lucas Meyer. He added that while progress is evident, the company remains unsatisfied and expects “lots more to come.”
